How to buy Adverum Biotechnologies stock (ADVM)

Adverum Biotechnologies is a biotechnology business based in the US. Adverum Biotechnologies shares (ADVM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.23 – a decrease of 11.8% over the previous week. Adverum Biotechnologies employs 121 staff and has a trailing 12-month revenue of around $1 million.

Our top picks for where to buy Adverum Biotechnologies stock

Buy Adverum Biotechnologies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Adverum Biotechnologies stock price (NASDAQ: ADVM)

Use our graph to track the performance of ADVM stocks over time.

Adverum Biotechnologies shares at a glance

• Key figures

Information last updated 2024-12-12.

Latest market close	$5.23
52-week range	$5.63 - $29.70
50-day moving average more info button	$7.21
200-day moving average more info button	$9.06
Wall St. target price	$29.71
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.95

Is it a good time to buy Adverum Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Adverum Biotechnologies price performance over time

Historical closes compared with the close of $5.26 from 2024-12-16

1 week (2024-12-11)	-11.30%
1 month (2024-11-18)	-23.21%
3 months (2024-09-18)	-24.75%
6 months (2024-06-18)	-20.18%

1 year (2023-12-18)	580.29%
2 years (2022-12-16)	-15.01%
3 years (2021-12-17)	17.7
5 years (2019-12-18)	109.4

Adverum Biotechnologies financials

Revenue TTM	$1 million
Gross profit TTM	$-81,681,000
Return on assets TTM	-29.83%
Return on equity TTM	-76.26%
Profit margin	0%
Book value	$6.93
Market Capitalization more info button	$123.4 million

TTM: trailing 12 months

Adverum Biotechnologies share dividends

We're not expecting Adverum Biotechnologies to pay a dividend over the next 12 months.

Have Adverum Biotechnologies's shares ever split?

Adverum Biotechnologies's shares were split on a 1:10 basis on 20 March 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adverum Biotechnologies shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Adverum Biotechnologies shares which in turn could have impacted Adverum Biotechnologies's share price.

Adverum Biotechnologies share price volatility

Over the last 12 months, Adverum Biotechnologies's shares have ranged in value from as little as $5.63 up to $29.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adverum Biotechnologies's is 1.008. This would suggest that Adverum Biotechnologies's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Adverum Biotechnologies overview

Adverum Biotechnologies, Inc. , a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV. 7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc.

Frequently asked questions

null
What percentage of Adverum Biotechnologies is owned by insiders or institutions?
Currently 11.668% of Adverum Biotechnologies shares are held by insiders and 79.164% by institutions. How many people work for Adverum Biotechnologies?
Latest data suggests 121 work at Adverum Biotechnologies. When does the fiscal year end for Adverum Biotechnologies?
Adverum Biotechnologies's fiscal year ends in December. Where is Adverum Biotechnologies based?
Adverum Biotechnologies's address is: 100 Cardinal Way, Redwood City, CA, United States, 94063 What is Adverum Biotechnologies's ISIN number?
Adverum Biotechnologies's international securities identification number is: US00773U1088 What is Adverum Biotechnologies's CUSIP number?
Adverum Biotechnologies's Committee on Uniform Securities Identification Procedures number is: 05337G107